Moleculin Biotech, Inc.

MBRX Nasdaq SEC CIK 1659617
Follow Moleculin Biotech Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$6.5M +74.4% vs same quarter last year
EPS, diluted −$9.59
Operating cash flow −$9M −24.2% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income11 fiscal years
  • Revenue
  • Net income
−$30M−$20M−$10M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0-
FY24$0-
FY23$0-
FY22$0−$29M
FY21$0−$15.9M
FY20$0−$17.4M
FY19$0−$13.2M
FY18$0−$11.9M
FY17$0−$9.8M
FY16$0−$3.9M
FY15--
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$22.7M
FY24−$23.9M
FY23−$23.7M
FY22−$27.7M
FY21−$19M
FY20−$18.1M
FY19−$17.3M
FY18−$12.6M
FY17−$7.4M
FY16−$3.8M
FY15-